At the recent Association of Women in Rheumatology annual conference, AWIR and ACR leaders discussed advocacy’s important role in supporting equitable rheumatologic care.
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.
A July 30 memo from Attorney General Pam Bondi clarifies how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion.
Practices that have experienced extreme circumstances—including wildfires or flooding—can apply for exceptions for Quality Payment Program reporting. Applications for 2025 are open through Dec. 31.
With 20 partner organizations, the ACR submitted a letter to HHS Secretary Robert F. Kennedy, Jr., urging the reinstatement of the terminated experts and reaffirming its commitment to science-based immunization policy.
The Insurance Subcommittee of the Committee on Rheumatologic Care is working on behalf of ACR members to address critical coverage and reimbursement challenges.
This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.
A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.